Lördag 23 November | 23:40:41 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-07 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning PHO 0.00 NOK
2024-05-23 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-09 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-05-04 - X-dag ordinarie utdelning PHO 0.00 NOK
2023-05-03 - Årsstämma
2023-02-24 - Bokslutskommuniké 2022
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-10 - Kvartalsrapport 2022-Q2
2022-05-11 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning PHO 0.00 NOK
2022-04-28 - Årsstämma
2022-02-23 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-11 - Kvartalsrapport 2021-Q2
2021-07-28 - Extra Bolagsstämma 2021
2021-05-21 - X-dag ordinarie utdelning PHO 0.00 NOK
2021-05-20 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-03-03 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning PHO 0.00 NOK
2020-06-10 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-07 - Kvartalsrapport 2019-Q2
2019-06-19 - Extra Bolagsstämma 2019
2019-05-14 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PHO 0.00 NOK
2019-05-09 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-23 - Kvartalsrapport 2018-Q1
2018-05-11 - X-dag ordinarie utdelning PHO 0.00 NOK
2018-05-09 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-23 - Kvartalsrapport 2017-Q1
2017-04-28 - X-dag ordinarie utdelning PHO 0.00 NOK
2017-04-27 - Årsstämma
2017-02-15 - Bokslutskommuniké 2016
2016-11-15 - Kvartalsrapport 2016-Q3
2016-08-23 - Kvartalsrapport 2016-Q2
2016-05-10 - Kvartalsrapport 2016-Q1
2016-04-29 - X-dag ordinarie utdelning PHO 0.00 NOK
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1
2015-05-02 - X-dag ordinarie utdelning PHO 0.00 NOK
2015-04-30 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-11-06 - Kvartalsrapport 2014-Q3
2014-08-26 - Kvartalsrapport 2014-Q2
2014-05-28 - X-dag ordinarie utdelning PHO 0.00 NOK
2014-05-27 - Årsstämma
2014-05-07 - Kvartalsrapport 2014-Q1
2014-02-27 - Bokslutskommuniké 2013
2013-10-23 - Kvartalsrapport 2013-Q3
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-23 - X-dag ordinarie utdelning
2013-05-22 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-24 - Kvartalsrapport 2012-Q2
2012-05-10 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-02-16 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-18 - Kvartalsrapport 2011-Q2
2011-04-27 - Årsstämma
2011-04-27 - Kvartalsrapport 2011-Q1
2011-02-17 - Bokslutskommuniké 2010
2010-10-27 - Kvartalsrapport 2010-Q3
2010-08-19 - Kvartalsrapport 2010-Q2
2010-04-28 - Kvartalsrapport 2010-Q1
2010-02-19 - Bokslutskommuniké 2009
2009-11-26 - X-dag bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2024-07-15 17:52:48
Oslo, Norway, July 15, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer
Company, today announces that it has entered into a strategic agreement with
Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high
-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's
System blue technology. The partnership between Photocure and Richard Wolf is
focused on developing technologically advanced flexible blue light cystoscopy
(BLC[®]) equipment for the global market so that physicians who treat patients
with bladder cancer can offer the benefits of BLC with Hexvix[®] / Cysview[®] in
an outpatient, or surveillance setting.

Under the Agreement, Richard Wolf will develop the new flexible BLC system with
input and guidance from Photocure, tapping into Photocure's extensive knowledge
of the surveillance procedure and the Company's experience with urology
customers. The new flexible blue light system and underlying intellectual
property will be owned by Richard Wolf, who will also serve as the sponsor of
market authorizations around the world. Photocure and Richard Wolf will share
expenses for the development and regulatory activities necessary for approvals
of the HD flexible blue light system in markets where it will be commercialized.

The strategic partnership between Photocure and Richard Wolf builds off a
longstanding relationship between the two companies associated with co
-promotion, disease awareness, education, market development, and clinical
research. Photocure and Richard Wolf will co-promote the new blue light flexible
system in the U.S., Europe and other countries globally.

Photocure will leverage its existing sales organization to promote the new
reusable flex system in North America and Europe, and will rely on Richard Wolf
distributors or commercial partners to co-promote the device in other markets.
Additionally, Photocure will utilize data from existing patient registries to
leverage real-world evidence to further support the benefits of flexible blue
light cystoscopy for patients with non-muscle invasive bladder cancer. Per the
agreement, Photocure and Richard Wolf will establish two governance committees
to oversee progress of the collaboration including a Joint Development Committee
to ensure R&D milestones are successfully achieved and a Joint Commercialization
Committee to execute pre- and post-approval go-to-market strategies globally.

New flexible BLC equipment has not been available for purchase since early 2023
in the U.S., as prior systems were outdated and discontinued by the
manufacturer. As a leading company focused on the management of bladder cancer,
Photocure is dedicated to ensuring that BLC with Hexvix/Cysview is available to
physicians worldwide in both the surgical and surveillance settings so that
patients with bladder cancer can have access to the best care.

"Entering into this partnership with Richard Wolf is a milestone for Photocure,
and more importantly is the first step toward making high-definition BLC
equipment in the surveillance setting consistently available for patients
globally," said Dan Schneider, President and CEO of Photocure. "Before the phase
-down of standard-definition flexible blue light equipment in the U.S., adoption
of these systems was on a strong growth path with physicians recognizing the
significant benefits of precision monitoring of bladder tumors with BLC and
Cysview. We look forward to working with Richard Wolf on the development and
anticipated commercialization of a 4K high-definition blue light cystoscope, and
bringing a cutting edge and cost-effective solution to physicians and patients
in our commercial territories as soon as possible."

"As a full-service provider in endoscopy and a leading manufacturer of blue
light cystoscopy equipment, we are very pleased to enter into this Agreement
with Photocure, to develop and commercialize a first-in-class/best-in-class high
-definition flexible blue light system," said Florian Happe, Vice President R&D
at Richard Wolf. "The workmanship that goes into every Richard Wolf device
provides the foundation for exceptional precision and longevity in the clinical
setting, enabling our institutional and physician customers to deliver
excellence in care to their patients. Surveillance of patients with bladder
cancer is of critical importance in disease management, and we believe that a
high-definition blue light cystoscope designed for out-patient use has potential
to set a new standard in this care setting."

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer worldwide - the 5th most
common in men - with 1949 000 prevalent cases (5-year prevalence rate)1a, 614000
new cases and more than 220000 deaths in 2022.1b
Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence
rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all cancers.3
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.4

1 Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].

2 Babjuk M, et al. Eur Urol. 2019